Keyphrases
Lenvatinib
52%
Unresectable Hepatocellular Carcinoma
46%
Hepatocellular Carcinoma
37%
Atezolizumab Plus Bevacizumab
33%
Hepatocellular Carcinoma Patients
24%
Overall Survival
17%
Advanced Hepatocellular Carcinoma
17%
Hazard Ratio
16%
Confidence Interval
16%
Albumin-bilirubin Grade
14%
Sorafenib
14%
Progression-free Survival
12%
Liver Disease
11%
Liver
10%
Hepatic Function
9%
Monoclonal Antibody
8%
Hepatitis B Virus
8%
Adverse Events
8%
Japan
7%
Tumor
7%
Hepatitis B Surface Antigen (HBsAg)
7%
Multivariate Analysis
7%
Bevacizumab Treatment
7%
Microwell Array
6%
Bevacizumab
6%
Array chip
6%
Inverse Probability Weighting
6%
Hepatitis B Virus Infection
6%
Nonalcoholic Steatohepatitis
6%
Atezolizumab
5%
Alpha-fetoprotein
5%
Therapeutic Efficacy
5%
Drug-induced Liver Injury
5%
Lymphocytes
5%
Antigen-specific Antibody
5%
Clinical Features
5%
Child-Pugh Score
5%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Lenvatinib
50%
Atezolizumab
40%
Bevacizumab
39%
Overall Survival
27%
Progression Free Survival
17%
Bilirubin
15%
Sorafenib
14%
Adverse Event
11%
Disease
10%
Liver Disease
9%
Combination Therapy
8%
Hepatitis B Virus
7%
Neoplasm
6%
Nonalcoholic Fatty Liver
6%
Liver Injury
6%
Liver Cirrhosis
6%
Chemotherapy
5%
Toxic Hepatitis
5%
Hepatitis B
5%
Liver Cancer
5%
Medicine and Dentistry
Hepatocellular Carcinoma
85%
Lenvatinib
46%
Atezolizumab
24%
Bevacizumab
23%
Overall Survival
17%
Lymphocyte
12%
Liver Function
12%
Neoplasm
12%
Hazard Ratio
12%
Progression Free Survival
11%
Bilirubin
11%
Liver Disease
9%
Adverse Event
8%
Sorafenib
7%
Disease
7%
Liver Cirrhosis
7%
Nonalcoholic Fatty Liver
7%
Hepatitis B Virus
7%
Neutrophil
6%
Radiofrequency Ablation
5%
Multivariate Analysis
5%
Prognostic Factor
5%
Chemotherapy
5%